Resistance Must Be Broken In The Fight Against Incurable Metastatic Breast Cancer
12/12/2012
One of the most frustrating truths about cancer is that even when a treatment works, it often doesn't work for long because cancer cells find ways to resist. However, researchers reporting studies done in mice in the December 11, 2012, issue of Cancer Cell, a Cell Press publication, may have a way to stay one step ahead in the case of aggressive metastatic breast cancer...
Apixaban Reduces Risk Of Recurrent Venous Thromboembolism
12/12/2012
A recent study finds that Eliquis (apixaban), an oral factor Xa inhibitor drug, is very effective at reducing the risk of recurrent venous thromboembolism. The drug being developed by Pfizer and Bristol-Myers Squibb is an anticoagulant; it works by preventing the formation of blood clots in veins by inhibiting an enzyme in the coagulation cascade...
The Significance Of Antibody Orientation
12/12/2012
The orientation of antibody binding to bacteria can mean life or death to the bug, according to a study published in The Journal of Experimental Medicine. These findings may help explain why these bacteria cause millions of localized infections, but more serious, systemic blood infections are rare...
Promising New Stem Cell Research, Transplant Strategies
12/12/2012
Studies of stem cell biology and transplant approaches presented at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) tran...
Addition of Everolimus to Exemestane Provides Sustained Edge in Women with Advanced Breast Cancer
12/11/2012
SAN ANTONIO - The progression-free survival (PFS) benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months in women with advanced breast cancer is maintained at 18- month follow-up, investigators announced at the San Antonio Breast Cancer Symposium (SABCS)...
SAN ANTONIO - The survival benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months in women with advanced breast cancer is maintained at 18- month follow-up, investigators announced at the San Antonio Breast Cancer Symposium (SABCS)...
Better Prostate Cancer Diagnosis - Image-Guided Biopsy
12/11/2012
Magnetic resonance ultrasound fusion targeted biopsy is a better way to accurately diagnose prostate cancer, scientists from the University of California, Los Angeles, have found. Prostate cancer is the sixth leading male cancer killer, and the most common cancer among American men. It develops very slowly over time and symptoms don't usually show until it has reached an advanced stage...
Child's Leukemia Cured By Her Own Re-Engineered Immune Cells
12/11/2012
Thanks to an experimental new therapy, a seven-year-old girl in the US with an aggressive form of childhood leukemia has been cured with her own re-engineered immune cells. After the treatment, her doctors could find no evidence of cancer...
Prostate Cancer Now Detectable By Targeted Biopsy, Potentially Ending 25-Year Era Of Blind Biopsy
12/11/2012
Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy...
More Than A Third Of High-Risk Leukemia Patients Respond To An Experimental New Drug
12/11/2012
A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial...